Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0RFWQY
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
ADRX-0706
|
|||||
| Synonyms |
ADRX-0706
Click to Show/Hide
|
|||||
| Organization |
Adcentrx Therapeutics (Originator)
|
|||||
| Drug Status |
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Antibody Name |
Anti-Nectin-4 antibody
|
Antibody Info | ||||
| Antigen Name |
Nectin-4 (NECTIN4)
|
Antigen Info | ||||
| Payload Name |
AP052
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Adcentrx' proprietary linker
|
Linker Info | ||||
| Conjugate Type |
Undisclosed
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Breast cancer |
1 Trials
|
||||||||
| Cervical cancer |
1 Trials
|
||||||||
| Urothelial cancer |
1 Trials
|
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible subjects for Phase 1a (dose escalation) must have select advanced solid tumors (e.g., UC, HNSCC, NSCLC) progressing after ≥1 prior therapy, while Phase 1b (dose expansion) focuses on UC, TNBC, or cervical cancer. Exclusions include uncontrolled CNS metastases, significant cardiovascular disease, recent anticancer therapy (<14 days/5 half-lives), and concurrent CYP3A/P-gp modifiers.
Click to Show/Hide
|
||||
| Administration Dosage |
.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06036121 | Clinical Status | PHASE1 | ||
| Clinical Description | A Phase 1a/b Study of ADRX-0706 in Subjects with Select Advanced Solid Tumors | ||||
| Primary Endpoint |
The study will evaluate the incidence of adverse events over an estimated 3-year period, assessing safety throughout the trial duration.
|
||||
| Other Endpoint |
Pharmacokinetic parameters (Cmax, Ctrough, AUC, t1/2, CL, Vss) of ADRX-0706 and immunogenicity via anti-drug antibodies (ADA) will be measured serially over 3 years. Efficacy endpoints include ORR, DOR, DCR, PFS, and OS, all assessed per RECIST 1.1 criteria.
|
||||